IL-10 Receptor Antibody Blocking for Cytokine Storm Suppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Cytokine storms caused by excessive production of pro-inflammatory cytokines like IL-6 and IL-10 in severe inflammatory diseases such as SARS-CoV-2, SFTS, and H5N1 lead to life-threatening hyperinflammation and multi-organ dysfunction, with existing therapies being inadequate.

Innovation Solution

Development of an antibody or antigen-binding fragment that specifically binds to the IL-10 receptor protein, inhibiting IL-10 signaling to reduce IL-6 production and increase TGF-β levels, thereby mitigating cytokine storms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing therapies are used to treat cytokine storms, then treatment is provided, but the therapies are inadequate and fail to effectively suppress excessive inflammation

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidexcessive inflammation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses an antibody as an intermediary substance that specifically binds to the IL-10 receptor, blocking the interaction between IL-10 and its receptor. This intermediary approach prevents the harmful signaling cascade that leads to excessive inflammation and cytokine storm, effectively resolving the contradiction between providing treatment and achieving adequate therapeutic efficacy.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the binding parameter by developing an antibody with high specificity and affinity for the IL-10 receptor. This parameter change enables effective blocking of IL-10 signaling, thereby suppressing excessive inflammation and improving therapeutic efficacy where existing therapies failed.

Inventive Principle:

Principle #35Parameter changes

2Quantity of substance

If IL-10 signaling is inhibited to reduce inflammation, then IL-6 production decreases, but the mechanism requires specific high-affinity binding to the IL-10 receptor

Engineering Contradiction:

ImproveIL-6 productionVSAvoidbinding specificity

Core Design Contradiction:

Quantity of substanceVSManufacturing precision

Solution Approach 1:

The patent applies local quality by designing an antibody that targets specifically to the IL-10 receptor with high precision. This localized specific binding ensures that the inhibition effect is concentrated at the intended target site, reducing IL-6 production through precise molecular interaction rather than broad nonspecific effects.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent replaces the natural IL-10 receptor binding mechanism with an antibody-mediated blocking mechanism. This substitution allows for controlled inhibition of IL-10 signaling, achieving reduction in IL-6 production while maintaining high binding specificity through the antibody's engineered affinity for the receptor.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentEP4653459A1Antibody specifically binding to il-10 receptor and use thereof

Publication Date: 2025.11.26 INDUSTRY UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY

Figure 1
Figure 2
Figure 3

AI summary

The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.